These ASOs-based studies have also investigated the combination of lncRNAs targeting with conventional MM therapies and demonstrated that MALAT1 and NEAT1 ASOs have synergistic effect with bortezomib, carfilzomib, melphalan and PARP1 inhibitor [27,28,130], providing the rationale for the use of lncRNA-specific ASOs in combo therapies. This evidence concerns the gene MALAT1 and Miyoshi myopathy.